

---

# Drug-Drug Interaction Assessment for Therapeutic Proteins Guidance for Industry

## ***DRAFT GUIDANCE***

**This guidance document is being distributed for comment purposes only.**

Comments and suggestions regarding this draft document should be submitted within 90 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit electronic comments to <https://www.regulations.gov>. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions regarding this draft document, contact (CDER) Office of Clinical Pharmacology Guidance and Policy Team at [CDER\\_OCP\\_GPT@fda.hhs.gov](mailto:CDER_OCP_GPT@fda.hhs.gov), (CBER) Office of Communications at [ocod@fda.hhs.gov](mailto:ocod@fda.hhs.gov), 800-835-4709, or 240-402-8010.

**U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research (CDER)  
Center for Biologics Evaluation and Research (CBER)**

**August 2020  
Clinical Pharmacology**

# Drug-Drug Interaction Assessment for Therapeutic Proteins Guidance for Industry

*Additional copies are available from:*  
*Office of Communications, Division of Drug Information*  
*Center for Drug Evaluation and Research*  
*Food and Drug Administration*  
*10001 New Hampshire Ave., Hillandale Bldg., 4<sup>th</sup> Floor*  
*Silver Spring, MD 20993-0002*  
*Phone: 855-543-3784 or 301-796-3400; Fax: 301-431-6353*  
*Email: [druginfo@fda.hhs.gov](mailto:druginfo@fda.hhs.gov)*

<https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm>

*and/or*  
*Office of Communication, Outreach, and Development*  
*Center for Biologics Evaluation and Research*  
*Food and Drug Administration*  
*10903 New Hampshire Ave., Bldg. 71, Room 3128*  
*Silver Spring, MD 20993-0002*  
*Phone: 800-835-4709 or 240-402-8010; Email: [ocod@fda.hhs.gov](mailto:ocod@fda.hhs.gov)*

<https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/biologics-guidances>

**U.S. Department of Health and Human Services**  
**Food and Drug Administration**  
**Center for Drug Evaluation and Research (CDER)**  
**Center for Biologics Evaluation and Research (CBER)**

**August 2020**  
**Clinical Pharmacology**

*Contains Nonbinding Recommendations*

*Draft — Not for Implementation*

**TABLE OF CONTENTS**

<b>I.</b>	<b>INTRODUCTION.....</b>	<b>1</b>
<b>II.</b>	<b>CONSIDERATIONS FOR ASSESSING DDIs FOR TPs.....</b>	<b>2</b>
<b>III.</b>	<b>TYPES OF DDI ASSESSMENTS AND STUDY DESIGN CONSIDERATIONS.....</b>	<b>5</b>
<b>IV.</b>	<b>LABELING RECOMMENDATIONS.....</b>	<b>6</b>
<b>V.</b>	<b>APPENDIX. TP-DDI DECISION TREE.....</b>	<b>8</b>

*Contains Nonbinding Recommendations*

*Draft — Not for Implementation*

**Drug-Drug Interaction Assessment for Therapeutic Proteins  
Guidance for Industry<sup>1</sup>**

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff responsible for this guidance as listed on the title page.

**I. INTRODUCTION**

The purpose of this guidance is to help sponsors of investigational new drug applications (INDs) and applicants of biologic license applications (BLAs) determine the need for drug-drug interaction (DDI) studies for a therapeutic protein (TP) by providing a systematic, risk-based approach.<sup>2,3</sup>

For the purpose of this guidance, a TP refers to a protein, licensed as a therapeutic biological product under section 351 of the Public Health Service Act (42 U.S.C. 262).<sup>4,5</sup> Although this guidance applies to therapeutic proteins, the general concepts could be applicable to other biological products, including biological products regulated by CBER such as cellular and gene therapies.

This guidance supplements the final FDA guidances entitled *In Vitro Drug Interaction Studies — Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions* and *Clinical Drug*

---

<sup>1</sup> This guidance has been prepared by the Therapeutic Protein DDI Working Group in the Office of Clinical Pharmacology in the Center for Drug Evaluation and Research in collaboration with the Center for Biologics Evaluation and Research at the Food and Drug Administration.

<sup>2</sup> Schrieber SJ, E Pfuma-Fletcher, X Wang, YC Wang, S Sagoo, R Madabushi, S Huang, and I Zineh, 2019, Considerations for Biologic Product Drug-Drug Interactions: A Regulatory Perspective, *Clin Pharmacol Ther*, 105:1332-1334.

<sup>3</sup> Hereafter, sponsors will refer to either applicants or sponsors.

<sup>4</sup> Section 351 of the Public Health Service Act, 42 U.S.C. § 282.

<sup>5</sup> Please refer to the FDA web page, *Transfer of Therapeutic Biological Products to the Center for Drug Evaluation and Research*, for more information about these products available at: <https://www.fda.gov/combination-products/classification-and-jurisdictional-information/transfer-therapeutic-biological-products-center-drug-evaluation-and-research>.

## ***Contains Nonbinding Recommendations***

*Draft — Not for Implementation*

27 *Interaction Studies — Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions*  
28 (January 2020).<sup>6</sup>  
29

30 In general, FDA’s guidance documents do not establish legally enforceable responsibilities.  
31 Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only  
32 as recommendations, unless specific regulatory or statutory requirements are cited. The use of  
33 the word *should* in Agency guidances means that something is suggested or recommended, but  
34 not required.  
35

### 36 37 **II. CONSIDERATIONS FOR ASSESSING DDIs FOR TPs** 38

39 When evaluating the potential for a DDI between a TP and small molecules or between TPs,  
40 sponsors should consider the mechanisms of a potential DDI, taking into account the  
41 pharmacology and clearance of the TP as well as any co-administered medications in the patient  
42 population.<sup>7</sup>  
43

44 Below, we provide examples of the types of situations in which an assessment of the DDI  
45 potential of a TP can be warranted. This list should not be considered all-inclusive, as the  
46 development of novel TPs will continue to inform the DDI risk. Also, refer to the decision tree in  
47 the Appendix for more information.  
48

#### 49 **A. Proinflammatory Cytokine-Related Mechanisms** 50

51 TPs that are proinflammatory cytokines (e.g., peginterferon) or TPs that cause increases in  
52 proinflammatory cytokine levels can down-regulate the expression of cytochrome P450 (CYP)  
53 enzymes, thereby decreasing the metabolism of drugs that are CYP substrates and increasing  
54 their exposure levels.<sup>8</sup> Conversely, TPs that reduce cytokine levels (e.g., TNF inhibitors) can  
55 relieve the CYP down-regulation from an inflammatory environment (e.g., rheumatoid arthritis),  
56 thereby increasing CYP expression and activity and reducing exposure for CYP substrates. Of  
57 note, therapies such as T-cell redirecting bispecific antibodies as well as certain cellular and gene  
58 therapies can cause cytokine release syndrome. Co-medication in some cases could be used to  
59 treat or prevent these increases in cytokines. These changes in cytokines have the potential to  
60 affect CYP expression as well as the activity and exposure for CYP substrates.  
61

##### 62 *1. The TP is a Proinflammatory Cytokine* 63

---

<sup>6</sup> For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

<sup>7</sup> Kraynov E, SW Martin, S Hurst, OA Fahmi, M Dowty, C Cronenberger, CM Loi, B Kuang, O Fields, S Fountain, M Awwad, and D Wang, 2011, How Current Understanding of Clearance Mechanisms and Pharmacodynamics of Therapeutic Proteins Can Be Applied for Evaluation of Their Drug-Drug Interaction Potential, *Drug Metab and Disp*, 39:1779-1783.

<sup>8</sup> Lee J, L Zhang, A Y Men, LA Kenna, and SM Huang, 2010, CYP-Mediated Drug-Therapeutic Protein Interactions: Clinical Findings, Proposed Mechanisms and Regulatory Implications, *Clin Pharmacokinet*, 49:295-310.

## ***Contains Nonbinding Recommendations***

*Draft — Not for Implementation*

64 The sponsor should evaluate the DDI potential for TPs that are proinflammatory cytokines.

65

66 2. *The TP is a Cytokine Modulator*

67

68 a. The TP causes an increase in proinflammatory cytokine levels

69

70 The increase in cytokine levels as a result of TP treatment can be transient or persistent.

71 Therefore, the sponsor should determine the time course and extent of this increase in cytokine

72 levels to help determine the need for a DDI study, the design of a study, and an appropriate

73 mitigation strategy, if necessary. If the sponsor determines that the DDI potential of the TP is

74 low, they should contact the FDA and provide justification for this determination (see

75 Appendix).

76

77 b. The TP modulates proinflammatory cytokines in conditions associated  
78 with elevated cytokine levels

79

80 Levels of proinflammatory cytokines differ by disease type and severity of disease, leading to  
81 variability in CYP expression. These considerations make it challenging to design a DDI study  
82 that can be extrapolated beyond the study population. Hence, the labeling for such  
83 proinflammatory cytokine modulators should include language indicating the potential for a  
84 DDI.

85

86 A sponsor can provide justification why they would prefer to not include the labeling language if  
87 they believe that the potential for clinically significant DDI is low.<sup>9</sup> Justification can include a  
88 discussion of:

89

90 • Effects seen with other agents or the same agent in other disease states with similar or  
91 more inflammatory burden

92

93 • Differences in exposure levels of sensitive CYP substrates in healthy subjects versus the  
94 indicated population

95

96 • The magnitude of the drug effect or the extent of cytokine modulation by the TP

97

98 Alternatively, the sponsor can perform a DDI study in the relevant indicated population to

99 further inform labeling. The disease type and severity and dose(s) used are important

100 considerations. Therefore, if a TP is being developed for multiple indications, the potential for

101 DDIs can be evaluated in the disease with the most severe inflammatory burden.

102

### **B. Mechanisms of DDIs Unrelated to Proinflammatory Cytokines**

104

105 Mechanisms unrelated to proinflammatory cytokines have been observed or postulated where the  
106 TP acts as a perpetrator (e.g., an inhibitor or inducer) or a victim of a small molecule or other TP

---

<sup>9</sup> Coutant DE and SD Hall SD, 2018, Disease-Drug Interactions in Inflammatory States Via Effects on CYP-Mediated Drug Clearance, *J Clin Pharmacol*, 58(7):849-863.

## ***Contains Nonbinding Recommendations***

*Draft — Not for Implementation*

107 DDI. Depending on the expected mechanism of the DDI, a TP could be evaluated as a victim or  
108 as a perpetrator. Scenarios when DDI evaluation should be considered include:

- 109
- 110 • When a TP affects human physiological processes that can in turn alter the  
111 pharmacokinetic profiles of co-administered medications (e.g., GLP-1 receptor agonists  
112 such as dulaglutide and albiglutide result in delayed gastric emptying). In this case, the  
113 sponsor should evaluate the TP as a perpetrator.  
114
  - 115 • Co-administered medications that impact the TP target or target-mediated disposition.<sup>10,11</sup>  
116 In these cases, depending on the role of the TP in the DDI, the sponsor should evaluate  
117 the DDI potential of the TP either as a perpetrator or as a victim.  
118
  - 119 • Co-administered medications that compromise the function of the FcRn can affect TPs  
120 which interact with the FcRn (e.g., blocking or interfering with the interaction between  
121 TPs containing an Fc region of human IgG and FcRn).<sup>12</sup> In these cases, the sponsor  
122 should evaluate the DDI potential of the TP as a victim.  
123
  - 124 • Co-administration of immunosuppressors with a TP whose pharmacokinetics are affected  
125 by immunogenicity (e.g., methotrexate on the clearance of adalimumab).<sup>5</sup> Since  
126 immunogenicity (i.e., the formation of antibodies to TPs) can alter the clearance of some  
127 TPs, drugs that suppress immunogenicity can change the clearance of a TP. In these  
128 cases, the sponsor should evaluate the DDI potential of the TP as a victim. This type of  
129 DDI evaluation can be difficult to prospectively design, in which case a descriptive  
130 analysis can often be considered adequate.

### **C. Antibody-Drug Conjugates**

134 For antibody-drug conjugates (ADCs), the small molecule drug component conjugated to the  
135 antibody component can be released into unconjugated form. Therefore, the DDI potential of  
136 both the antibody and the small molecule drug components should be evaluated as described  
137 below:

- 138
- 139 • For the antibody component, consider the categories described above (see Section II) to  
140 determine if a DDI assessment is warranted.  
141
  - 142 • For the small molecule drug component, follow the considerations described in the final  
143 FDA guidances for industry entitled *In Vitro Drug Interaction Studies — Cytochrome*

---

<sup>10</sup> Abuqayyas L, JP Balthasar JP, 2012, Pharmacokinetic mAb-mAb Interaction: Anti-VEGF mAb Decreases the Distribution of Anti-CEA mAb into Colorectal Tumor Xenografts, AAPS J, 14(3):445–55.

<sup>11</sup> Pastuskovas CV, EE Mundo, SP Williams, et al, 2012, Effects of Anti-VEGF on Pharmacokinetics, Biodistribution, and Tumor Penetration of Trastuzumab in a Preclinical Breast Cancer Model, Mol Cancer Ther, 11(3):752-62.

<sup>12</sup> Kiessling P, R Lledo-Garcia, S Watanabe, et al, 2017, The FcRn Inhibitor Rozanolixizumab Reduces Human Serum IgG Concentration: A Randomized Phase I Study, Sci Transl Med, 9(414):1208.

## ***Contains Nonbinding Recommendations***

*Draft — Not for Implementation*

144 *P450 Enzyme- and Transporter-Mediated Drug Interactions and Clinical Drug*  
145 *Interaction Studies — Cytochrome P450 Enzyme- and Transporter-Mediated Drug*  
146 *Interactions* (January 2020).  
147

148 It is important to understand the systemic exposure of the small molecule drug component of the  
149 ADC. In many cases, the systemic concentration might be too low to act as a perpetrator. It  
150 might be necessary to evaluate the small molecule component (administered as an ADC) as a  
151 victim drug. Understanding the exposure-response relationship of the various moieties is  
152 important in determining the need for and significance of DDI studies. For example, if systemic  
153 concentrations of the free small molecule drug are low, evaluating the effect of strong CYP3A  
154 inducers on the drug's pharmacokinetics might not be necessary if the free small molecule drug  
155 in circulation is not contributing to efficacy. However, a study with a strong inhibitor could be  
156 necessary due to the potential for safety concerns associated with the increase in concentration of  
157 the free small molecule drug in the circulation. Although there are limitations in the ability to  
158 modify the dose of an ADC, the sponsor should seek to understand whether a drug can be safely  
159 used concomitantly with the ADC.  
160

### **III. TYPES OF DDI ASSESSMENTS AND STUDY DESIGN CONSIDERATIONS**

162  
163

164 Using a systematic, science-driven approach to evaluate the DDI potential of TPs is highly  
165 recommended and can involve a combination of the assessment types listed below. Sponsors  
166 should consider the DDI risk of their product early in development and summarize their DDI  
167 program at milestone meetings with the FDA. Potential discussion topics at these meetings  
168 include the need for and planning, timing, and study design of DDI evaluations for the  
169 investigational drug.  
170

#### **A. In Vitro and Animal Studies**

171  
172

173 The translation of in vitro data or animal data to humans has been limited. However, some  
174 methods could provide mechanistic understanding of the DDI potential of a TP and in some  
175 cases be combined with physiologically based pharmacokinetic (PBPK) models.  
176 Recommendations on the use of in vitro and animal studies may be further updated once relevant  
177 models are validated for their intended use. In vitro DDI evaluation for the small molecule drug  
178 component of an ADC should be performed consistent with the final FDA guidance for industry  
179 entitled *In Vitro Drug Interaction Studies — Cytochrome P450 Enzyme- and Transporter-*  
180 *Mediated Drug Interactions* (January 2020) (see Section IIC).  
181

#### **B. Clinical Studies**

182  
183

184 Clinical studies of TPs should consider the suspected mechanism for the DDI when selecting the  
185 relevant study population and the interacting drugs to evaluate. The study design (parallel or  
186 crossover) should be informed by the suspected mechanism of the DDI and the pharmacokinetic  
187 (PK) characteristics of the drugs (e.g., the drug's half-life).  
188



## ***Contains Nonbinding Recommendations***

*Draft — Not for Implementation*

189 For TPs with a long half-life, a parallel design might be appropriate in evaluating the TP as a  
190 victim. A single sequence crossover design (substrate followed by the substrate plus the TP) can  
191 be used when evaluating the TP as a perpetrator (e.g., the effect of proinflammatory cytokines or  
192 cytokine modulators on CYP substrates). The sponsor should determine the time course for  
193 cytokine modulation by the TP in the specific disease state to guide the timing and duration of  
194 administration of substrate and TP in the study. A cocktail approach is an efficient means of  
195 evaluating the DDI for TPs where multiple CYPs could be impacted (e.g., proinflammatory  
196 cytokines and cytokine modulators).

### **C. Population PK Modeling (Nested DDI Studies)**

197  
198  
199  
200 Population PK analyses can be informative in the evaluation of DDIs for TPs.<sup>13,14</sup> A population  
201 PK analysis for prospective DDI evaluation should have carefully designed study procedures and  
202 protocols for the collection of PK samples. In general, this approach can be used to evaluate the  
203 effect of other agents on the investigational TP as PK data are usually only collected for the  
204 investigational agent. However, a sponsor can prospectively plan and collect the necessary data  
205 for a substrate of interest to support the evaluation of the investigational TP as a perpetrator. For  
206 a discussion on nested DDI studies, refer to the final FDA guidance entitled *Clinical Drug*  
207 *Interaction Studies — Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions*  
208 (January 2020) and the draft FDA guidance entitled *Population Pharmacokinetics* (July 2019).<sup>15</sup>

### **D. Physiologically Based PK Modeling**

209  
210  
211  
212 The application of PBPK modeling in the evaluation of the DDI potential of a TP is an emerging  
213 area. PBPK modeling has a potential role in understanding the underlying mechanism of a DDI.  
214 Sponsors are encouraged to contact the FDA when proposing to use PBPK modeling to evaluate  
215 the DDI potential of TPs. For more information, see the FDA final guidance entitled  
216 *Physiologically Based Pharmacokinetic Analyses — Format and Content* (September 2018).

## **IV. LABELING RECOMMENDATIONS**

217  
218  
219  
220  
221 Prescribing Information must include a summary of essential DDI information needed for the  
222 safe and effective use of the drug by the health care provider.<sup>16</sup> For specific requirements and  
223 recommendations regarding how to incorporate DDI information in labeling, refer to 21 CFR  
224 201.57 and the following final FDA guidances:

---

<sup>13</sup> Chow AT, JC Earp, M Gupta, W Hanley, C Hu, DD Wang, S Zajic, and M Zhu, 2014, Population PK TPDI Working Group: Utility of Population Pharmacokinetic Modeling in the Assessment of Therapeutic Protein-Drug Interactions, *J Clin Pharmacol*, 54:593-601.

<sup>14</sup> Kenny JR, MM Liu, AT Chow, JC Earp, R Evers, JG Slatter, DD Wang, L Zhang, and H Zhou, 2013, Therapeutic Protein Drug-Drug Interactions: Navigating the Knowledge Gaps—Highlights from the 2012 AAPS NBC Roundtable and IQ Consortium/FDA Workshop, *AAPS J*, 15:993-940.

<sup>15</sup> When final, this guidance will represent the FDA's current thinking on this topic.

<sup>16</sup> 21 CFR 201.56(a)(1)

## ***Contains Nonbinding Recommendations***


*Draft — Not for Implementation*

- 225
- 226
- 227
- 228
- 229
- 230
- 231
- 232
- 233
- 234
- 235
- 236
- 237
- *Labeling for Human Prescription Drug and Biological Products – Implementing the PLR Content and Format Requirements* (February 2013)
  - *Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Products — Content and Format* (March 2010)
  - *Warnings and Precautions, Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drug and Biological Products — Content and Format* (October 2011)
  - *Clinical Pharmacology Section of Labeling for Human Prescription Drug and Biological Products — Content and Format* (December 2016)

## Contains Nonbinding Recommendations

Draft — Not for Implementation

### 238 V. APPENDIX. TP-DDI DECISION TREE 239



\*The Agency recommends that DDI evaluation proposals be discussed with the appropriate review division prior to initiating a study.

240